ATyr Pharma Operating Income Over Time
| ATYR Stock | 1.04 0.01 0.95% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ATyr Pharma Performance and ATyr Pharma Correlation. Can Biotechnology industry sustain growth momentum? Does ATyr have expansion opportunities? Factors like these will boost the valuation of ATyr Pharma. If investors know ATyr will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating ATyr Pharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of aTyr Pharma is measured differently than its book value, which is the value of ATyr that is recorded on the company's balance sheet. Investors also form their own opinion of ATyr Pharma's value that differs from its market value or its book value, called intrinsic value, which is ATyr Pharma's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because ATyr Pharma's market value can be influenced by many factors that don't directly affect ATyr Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that ATyr Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ATyr Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, ATyr Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare aTyr Pharma and related stocks such as Alx Oncology Holdings, CAMP4 THERAPEUTICS, and Quince Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALXO | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (19.2 M) | (43.7 M) | (83.6 M) | (127.4 M) | (170.3 M) | (142.5 M) | (128.2 M) | (134.6 M) |
| CAMP | (6.3 M) | 7.4 M | 16 M | 18.3 M | 24.9 M | 28.1 M | 1.3 M | 8 M | 19.7 M | (16.8 M) | (3.9 M) | (15.3 M) | (45 M) | (51.9 M) | (53.1 M) | (47.8 M) | (45.4 M) |
| QNCX | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (12.1 M) | (39.2 M) | (78.9 M) | (90.3 M) | (52 M) | (34.6 M) | (57.3 M) | (51.6 M) | (54.1 M) |
| MGX | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (44.6 M) | (78.5 M) | (88.9 M) | (88.9 M) | (80 M) | (84 M) |
| RPTX | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (12.8 M) | (25.8 M) | (54.3 M) | (108.7 M) | (19.8 M) | (116.2 M) | (93.5 M) | (84.2 M) | (88.4 M) |
| UNCY | (952 K) | (952 K) | (952 K) | (952 K) | (952 K) | (952 K) | (952 K) | (952 K) | (952 K) | (2 M) | (2 M) | (9 M) | (18.1 M) | (20.8 M) | (32.1 M) | (28.9 M) | (27.5 M) |
| RLMD | (12.1 K) | (12.1 K) | (12.1 K) | (45 K) | (17.1 M) | (17.1 M) | (16.2 M) | (7.2 M) | (6.9 M) | (15.1 M) | (60.8 M) | (125.7 M) | (161.2 M) | (103.7 M) | (83.9 M) | (75.5 M) | (79.3 M) |
| ACRV | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (16.2 M) | (32.7 M) | (67.2 M) | (89.2 M) | (80.3 M) | (76.3 M) |
| HYFT | (221.6 K) | (213.3 K) | (81.9 K) | (95.4 K) | (66 K) | (34.4 K) | (1.4 M) | (4.8 M) | (6.4 M) | (4.3 M) | (3.9 M) | (17.1 M) | (29.3 M) | (14.3 M) | (12.3 M) | (11 M) | (10.5 M) |
| DTIL | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (22 M) | (47.9 M) | (87.2 M) | (109.8 M) | (39.4 M) | (62.3 M) | (43.7 M) | (26.2 M) | (23.5 M) | (24.7 M) |
aTyr Pharma and related stocks such as Alx Oncology Holdings, CAMP4 THERAPEUTICS, and Quince Therapeutics Operating Income description
Operating Income is the amount of profit realized from aTyr Pharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of aTyr Pharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| aTyr Pharma | ATYR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 10240 Sorrento Valley |
| Exchange | NASDAQ Exchange |
null 1.04
Additional Tools for ATyr Stock Analysis
When running ATyr Pharma's price analysis, check to measure ATyr Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma is operating at the current time. Most of ATyr Pharma's value examination focuses on studying past and present price action to predict the probability of ATyr Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma's price. Additionally, you may evaluate how the addition of ATyr Pharma to your portfolios can decrease your overall portfolio volatility.